

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

| | |
|--------------------|--|
| Name | Park, Joo Kyung |
| Affiliation | Republic of Korea (South Korea) |
| Country | Samsung Medical Center Sungkyunkwan University School of Medicine |
| Major Field | Gastroenterology, Pancreatobiliary Section |

Educational Background

| | | |
|-------------|-------|--|
| 1994 - 2000 | M.D. | Seoul National University College of Medicine |
| 2003 - 2005 | M.S. | Graduate School, Seoul National University College of Medicine |
| 2009 - 2014 | Ph.D. | Graduate School, Seoul National University College of Medicine |

Professional Experience

2004 Resident Dept. Internal Medicine, Seoul National University Hospital
2007 Fellow Dept. Internal Medicine, Seoul National University Hospital
2009 Assistant Professor Dept. Internal Medicine, Seoul National University Hospital
2011 Post-Doctoral Research Fellow, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2014 Associate Professor Dept. of Internal Medicine, Seoul National University Hospital
2015 ~ 2018 Associate Professor Dept. Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
2018 ~ Present Professor Dept. Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Main Scientific Publications

1. [Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.](#) Park JK, Jeong HO, Kim H, Choi JH, Lee EM, Kim S, Jang J, Choi DW, Lee SH, Kim KM, Jang KT, Lee KH, Lee KT, Lee MW, Lee JK, Lee S. Mol Cancer. 2024 May 3;23(1):87. doi: 10.1186/s12943-024-02003-0. (제 1 저자, IF 37.1)
2. [Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adenocarcinoma \(with video\).](#) Kim H, Jang J, Choi JH, Song JH, Lee SH, Park J, Ryoo SK, Lee EM, Jeong HO, Kim S, Lee SH, Lee KH, Lee KT, Kim KM, Jang KT, Lee H, Lee S, Lee JK, Park JK. Gastrointest Endosc. 2024 Jul;100(1):85-96.e9. doi: 10.1016/j.gie.2024.02.021. (교신저자, IF 7.7)
3. [Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial.](#) Paik WH, Park JK, Chung MJ, Huh G, Park CH, Lee SH, Jeong HS, Kim HJ, Park DH. Clin Mol Hepatol. 2024 Sep 24. doi: 10.3350/cmh.2024.0629. (제 1 저자, IF 14.0)



Main Scientific Publications

4. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. Koh Y, Kim H, Joo SY, Song S, Choi YH, Kim HR, Moon B, Byun J, Hong J, Shin DY, Park S, Lee KH, Lee KT, Lee JK, Park D, Lee SH, Jang JY, Lee H, Kim JA, Yoon SS, **Park JK**. J Transl Med. 2023 Oct 17;21(1):730. doi: 10.1186/s12967-023-04549-x.PMID: 37848935 (교신저자, IF 8.4)
5. Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study. Park JH, Hong JY, Kwon M, Lee J, Han K, Han IW, Kang W, **Park JK**. Eur J Cancer. 2021 Jun;150:73-82. doi: 10.1016/j.ejca.2021.03.024. (교신저자, IF 10.0)
6. Characterization of background noise in capture-based targeted sequencing data. Park G, **Park JK**, Shin SH, Jeon HJ, Kim NKD, Kim YJ, Shin HT, Lee E, Lee KH, Son DS, Park WY, Park D. Genome Biol. 2017 Jul 21;18(1):136. doi: 10.1186/s13059-017-1275-2. PMID: 28732520 Free PMC article. (제1저자 IF 12.3)
7. Efficacy of EUS-guided and ERCP-guided biliary drainage for malignant biliary obstruction: a prospective randomized controlled study. **Park JK**, Woo YS, Noh DH, Yang JI, Bae SY, Yun HS, Lee JK, Lee KT, Lee KH. Gastrointest Endosc. 2018 Aug;88(2):277-282. doi: 10.1016/j.gie.2018.03.015. Epub 2018 Mar 30.PMID: 29605722 Clinical Trial. (제1저자, IF 7.7)
8. Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. Park JH, Hong JY, Han K, Kang W, **Park JK**. Sci Rep. 2022 Jun 23;12(1):10681. doi: 10.1038/s41598-022-14856-w. (교신저자)
9. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Kim H, Heo CM, Oh J, Chung HH, Lee EM, Park J, Lee SH, Lee KH, Lee KT, Lee JK, Cho YK, **Park JK**. Transl Oncol. 2022 Feb;16:101321. doi: 10.1016/j.tranon.2021.101321. Epub 2021 Dec 23. (교신저자)
10. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. **Park JK**, Kim H, Son DS, Kim NKD, Sung YK, Cho M, Lee C, Noh DH, Lee SH, Lee KT, Lee JK, Jang KT, Park WY, Lee KH. Cancers (Basel). 2021 Jun 3;13(11):2791. doi: 10.3390/cancers13112791. (교신저자)
11. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. Park G, **Park JK**, Son DS, Shin SH, Kim YJ, Jeon HJ, Lee J, Park WY, Lee KH, Park D. Sci Rep. 2018 Aug 2;8(1):11631. doi: 10.1038/s41598-018-30100-w. (제 1 저자)